Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Bulletin Du Cancer|March 19, 2011
[Metastatic cutaneous hematoma variant from melanoma: five cases]Anne Pham-Ledard, Alain Taieb, Béatrice Vergier, et al.
Dermatology (Basel, Switzerland)|December 24, 2009
Disseminated cutaneous lymphoid hyperplasia of 12 years' duration triggered by vaccinationAnne Pham-Ledard, Beatrice Vergier, Marie-Sylvie Doutre, et al.
British Journal of Clinical Pharmacology|December 9, 2020
Safety profile of drugs for advanced melanoma: A report based on 2008-2018 US Food and Drug Administration DataEmilie Casarotto, Pernelle Noize, Louis Létinier, et al.
European Journal of Cancer (Oxford, England : 1990)|December 19, 2023
Clinical impact of proton pump inhibitors and other co-medications on advanced melanoma patients treated with BRAF/MEK inhibitorsEloïse Ramel, Sorilla Prey, Caroline Dutriaux, et al.
Clinical Nuclear Medicine|June 3, 2017
18F-FDG PET/CT Imaging of Popliteal Vasculitis Associated With Polyarteritis NodosaRomain Schollhammer, Paul Schwartz, Marie-Laure Jullie, et al.
The American Journal of Surgical Pathology|November 8, 2017
PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg TypeSarah Menguy, Martina Prochazkova-Carlotti, Marie Beylot-Barry, et al.
Melanoma Research|March 15, 2023
Real-life use of trametinib after immunotherapy failure in BRAF wild-type advanced melanomaTristan Pigné, Marie Lévy, Océane Ducharme, et al.
The Journal of Investigative Dermatology|October 9, 2009
IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 casesAnne Pham-Ledard, Martina Prochazkova-Carlotti, Elodie Laharanne, et al.
Cancer Immunology, Immunotherapy : CII|January 21, 2019
Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanomaVaianu Leroy, Emilie Gerard, Caroline Dutriaux, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|April 17, 2017
An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patientsMarine Rousset, Karine Titier, Stephane Bouchet, et al.
Pageof 6